Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (71-80 of 208) with videos related to

Pageof 21
Sort By:
Urologic Oncology|August 25, 2024
Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan AfricaMusliu Adetola Tolani, Ismail Hadi Zubairu, Kabir Balarabe, et al.
Translational Oncology|December 26, 2022
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trialJuana Martinez, Kritika Subramanian, Sandra Huicochea Castellanos, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
BJU International|August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomyScott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Lab on a Chip|December 22, 2009
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyJason P Gleghorn, Erica D Pratt, Denise Denning, et al.
BJU International|November 1, 2011
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)Daniel J Lee, Eugene K Cha, Justin M Dubin, et al.
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Pageof 21

Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Urologic Oncology|August 25, 2024
Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan AfricaMusliu Adetola Tolani, Ismail Hadi Zubairu, Kabir Balarabe, et al.
Translational Oncology|December 26, 2022
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trialJuana Martinez, Kritika Subramanian, Sandra Huicochea Castellanos, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
BJU International|August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomyScott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Lab on a Chip|December 22, 2009
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyJason P Gleghorn, Erica D Pratt, Denise Denning, et al.
BJU International|November 1, 2011
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)Daniel J Lee, Eugene K Cha, Justin M Dubin, et al.
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Pageof 21